Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on ...

Palatin Technologies, Inc. (the "Company") (NYSE American:PTN), a biopharmaceutical company developing first-in-class ...

US biopharma company Palatin Technologies (NYSE American: PTN) is at risk of being removed from the NYSE American exchange ...

Technologies announced today that on April 10, NYSE American publicly announced and provided a notice to the company that NYSE ...

Palatin is advancing the development of its next-generation MC4R long-acting peptide and oral small molecule compounds for the treatment of general obesity, weight loss management, acquired and ...

(RTTNews) - Palatin Technologies, Inc. (PTN), Thursday announced positive data from the Phase 2b BREAKOUT study of a melanocortin agonist in patients with diabetic Type 2 nephropathy. The six ...

Technologies announced that its BMT-801 Phase 2 obesity co-administration study met its primary endpoint and was highly ...

Clinical Remission: Achieved in 33% of PL8177-treated patients versus 0% on placebo after eight weeks of treatment. Clinical Response (statistically significant): Demonstrated in 78% of PL8177 ...

Phase 1 SAD/MAD studies to include hypothalamic obesity patients. CRANBURY, N.J., March 31, 2025 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in ...